100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44CA224503
Award Date
4/1/18
Completion Date
8/31/23
Dollars Obligated
$3.7M
Overview
Activity
6
Transactions
6
Subawards
Similar Awards
Federal Agency
National Cancer Institute
Awardee
Rarecyte, Inc. (N6CVCHBTWT86)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98121, USA
Update #1
Update #2
RAPID HIGHLY MULTI-PLEXED IMMUNO-PROFILING OF SOLID TUMORS BY SPECTRALEDGE IMAGING
Posted 9/9/20
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
RAPID HIGHLY MULTI-PLEXED IMMUNO-PROFILING OF SOLID TUMORS BY SPECTRALEDGE IMAGING - PROJECT SUMMARY - ABSTRACT THE DRAMATIC IMPACT OF IMMUNE CHECKPOINT INHIBITORS (ICIS) HAS FOCUSED INTEREST IN INVESTIGATING IMMUNE-TUMOR CELL INTERACTIONS TO UNDERSTAND MECHANISMS OF ICI SENSITIVITY AND RESISTANCE, TO IDENTIFY PATIENTS RESPONSIVE TO SPECIFIC DRUGS, AND TO DEVELOP NEW THERAPIES. MULTIPLEXED TISSUE IMAGING IS A HIGHLY PROMISING APPROACH TO TUMOR IMMUNOPROFILING: IT CAN ASSESS MANY CELL TYPES AND STATES WITHIN THE CONTEXT OF PRESERVED TUMOR ARCHITECTURE AND IS COMPATIBLE WITH PATHOLOGY WORKFLOWS. A CRITICAL UNMET NEED EXISTS FOR MULTIPLEX TECHNOLOGY WITH THE FOLLOWING CAPABILITIES: (1) WHOLE-SLIDE IMAGING; (2) RAPID SINGLE-PASS DATA COLLECTION; (3) SUB- CELLULAR IMAGING RESOLUTION; (4) SUFFICIENT IMMUNOPROFILING DEPTH; (5) BRIGHT-FIELD IMAGING CAPABILITY; (6) OPTICAL AND MECHANICAL STABILITY FOR ACCURATE IMAGE TILE STITCHING; (7) AVAILABILITY OF CORE AND CUSTOMIZABLE ANTIBODY PANEL KITS FOR PROFILING; AND (8) COMPATIBILITY WITH ESTABLISHED IMAGE DATA STANDARDS AND FORMATS. THIS RARECYTE - HARVARD MEDICAL SCHOOL PHASE II PROPOSAL DESCRIBES SPECTRALEDGETM, A BREAKTHROUGH IMAGING TECHNOLOGY THAT MEETS THESE REQUIREMENTS, PERFORMING HIGH-RESOLUTION HIGH-PLEX WHOLE-SLIDE IMAGING OF 20 ANTIGENS LABELLED WITH FLUOROPHORE-CONJUGATED ANTIBODIES IN A SINGLE-PASS SCAN OF LESS THAN 1 HOUR. THE PATENTED SPECTRALEDGE METHOD INVOLVES A NOVEL INSTRUMENT AND SOFTWARE AS WELL AS HIGHLY VALIDATED TISSUEPLEXTM ANTIBODY PANELS. SPECTRALEDGE IMAGING WILL ACCELERATE DISCOVERY OF PREDICTIVE AND PROGNOSTIC BIOMARKERS, ENABLE PHARMACODYNAMICS STUDY OF IMMUNO-ONCOLOGY DRUGS UNDERGOING CLINICAL TRIALS AND ULTIMATELY PROVIDE CLINICALLY ACTIONABLE DIAGNOSTIC TESTS. AIM 1 WILL FOCUS ON ENGINEERING AND PRODUCTION OF A ROBUST, PRODUCTION-READY SLIDE SCANNER AND SOFTWARE FOR RAPID HIGH-RESOLUTION 20-PLEX SPECTRALEDGE WHOLE-SLIDE IMAGING; IT WILL BE BASED ON RARECYTE'S EXISTING CYTEFINDER II IMAGING SYSTEM. PRODUCTION OF A RESEARCH-USE-ONLY INSTRUMENT AND REAGENTS TO ISO13485 STANDARDS WILL ENABLE SUBSEQUENT DEPLOYMENT IN A CLINICAL SETTING. COMPATIBILITY WITH CURRENT AND EMERGING DATA FORMAT AND SOFTWARE STANDARDS WILL ENABLE INTEGRATION WITH DIVERSE RESEARCH AND CLINICAL WORKSTREAMS. AIM 2 WILL TEST AND VALIDATE MODULAR ANTIBODY PANELS FOR IMMUNOPHENOTYPING AND TUMOR CELL IMAGING ACROSS A RANGE OF TUMOR TYPES. THIS WILL YIELD VALIDATED TISSUEPLEX PANELS HAVING A CORE SET OF IMMUNOPROFILING ANTIBODIES AND ANTIBODY "MODULES" FOR INDIVIDUAL TUMOR TYPES. AIM 3 WILL TEST SPECTRALEDGE IMAGING ON WELL-CHARACTERIZED SAMPLE COHORTS IN: (I) TRANSLATIONAL BIOMARKER DISCOVERY, (II) INDUSTRY-SPONSORED AND INVESTIGATOR-INITIATED IMMUNO-ONCOLOGY TRIALS, (III) MOUSE MODELS OF CANCER, AND (IV) CLINICAL SPECIMENS CURRENTLY UNDERGOING IMMUNOPROFILING WITH OTHER DIAGNOSTIC METHODS. CLINICAL SAMPLE STUDIES WILL BE OVERSEEN BY AN ADVISORY GROUP OF BOARD-CERTIFIED HMS PATHOLOGISTS.
$0
4/22/24
Not listed
RAPID HIGHLY MULTI-PLEXED IMMUNO-PROFILING OF SOLID TUMORS BY SPECTRALEDGE IMAGING - PROJECT SUMMARY - ABSTRACT THE DRAMATIC IMPACT OF IMMUNE CHECKPOINT INHIBITORS (ICIS) HAS FOCUSED INTEREST IN INVESTIGATING IMMUNE-TUMOR CELL INTERACTIONS TO UNDERSTAND MECHANISMS OF ICI SENSITIVITY AND RESISTANCE, TO IDENTIFY PATIENTS RESPONSIVE TO SPECIFIC DRUGS, AND TO DEVELOP NEW THERAPIES. MULTIPLEXED TISSUE IMAGING IS A HIGHLY PROMISING APPROACH TO TUMOR IMMUNOPROFILING: IT CAN ASSESS MANY CELL TYPES AND STATES WITHIN THE CONTEXT OF PRESERVED TUMOR ARCHITECTURE AND IS COMPATIBLE WITH PATHOLOGY WORKFLOWS. A CRITICAL UNMET NEED EXISTS FOR MULTIPLEX TECHNOLOGY WITH THE FOLLOWING CAPABILITIES: (1) WHOLE-SLIDE IMAGING; (2) RAPID SINGLE-PASS DATA COLLECTION; (3) SUB- CELLULAR IMAGING RESOLUTION; (4) SUFFICIENT IMMUNOPROFILING DEPTH; (5) BRIGHT-FIELD IMAGING CAPABILITY; (6) OPTICAL AND MECHANICAL STABILITY FOR ACCURATE IMAGE TILE STITCHING; (7) AVAILABILITY OF CORE AND CUSTOMIZABLE ANTIBODY PANEL KITS FOR PROFILING; AND (8) COMPATIBILITY WITH ESTABLISHED IMAGE DATA STANDARDS AND FORMATS. THIS RARECYTE - HARVARD MEDICAL SCHOOL PHASE II PROPOSAL DESCRIBES SPECTRALEDGETM, A BREAKTHROUGH IMAGING TECHNOLOGY THAT MEETS THESE REQUIREMENTS, PERFORMING HIGH-RESOLUTION HIGH-PLEX WHOLE-SLIDE IMAGING OF 20 ANTIGENS LABELLED WITH FLUOROPHORE-CONJUGATED ANTIBODIES IN A SINGLE-PASS SCAN OF LESS THAN 1 HOUR. THE PATENTED SPECTRALEDGE METHOD INVOLVES A NOVEL INSTRUMENT AND SOFTWARE AS WELL AS HIGHLY VALIDATED TISSUEPLEXTM ANTIBODY PANELS. SPECTRALEDGE IMAGING WILL ACCELERATE DISCOVERY OF PREDICTIVE AND PROGNOSTIC BIOMARKERS, ENABLE PHARMACODYNAMICS STUDY OF IMMUNO-ONCOLOGY DRUGS UNDERGOING CLINICAL TRIALS AND ULTIMATELY PROVIDE CLINICALLY ACTIONABLE DIAGNOSTIC TESTS. AIM 1 WILL FOCUS ON ENGINEERING AND PRODUCTION OF A ROBUST, PRODUCTION-READY SLIDE SCANNER AND SOFTWARE FOR RAPID HIGH-RESOLUTION 20-PLEX SPECTRALEDGE WHOLE-SLIDE IMAGING; IT WILL BE BASED ON RARECYTE'S EXISTING CYTEFINDER II IMAGING SYSTEM. PRODUCTION OF A RESEARCH-USE-ONLY INSTRUMENT AND REAGENTS TO ISO13485 STANDARDS WILL ENABLE SUBSEQUENT DEPLOYMENT IN A CLINICAL SETTING. COMPATIBILITY WITH CURRENT AND EMERGING DATA FORMAT AND SOFTWARE STANDARDS WILL ENABLE INTEGRATION WITH DIVERSE RESEARCH AND CLINICAL WORKSTREAMS. AIM 2 WILL TEST AND VALIDATE MODULAR ANTIBODY PANELS FOR IMMUNOPHENOTYPING AND TUMOR CELL IMAGING ACROSS A RANGE OF TUMOR TYPES. THIS WILL YIELD VALIDATED TISSUEPLEX PANELS HAVING A CORE SET OF IMMUNOPROFILING ANTIBODIES AND ANTIBODY "MODULES" FOR INDIVIDUAL TUMOR TYPES. AIM 3 WILL TEST SPECTRALEDGE IMAGING ON WELL-CHARACTERIZED SAMPLE COHORTS IN: (I) TRANSLATIONAL BIOMARKER DISCOVERY, (II) INDUSTRY-SPONSORED AND INVESTIGATOR-INITIATED IMMUNO-ONCOLOGY TRIALS, (III) MOUSE MODELS OF CANCER, AND (IV) CLINICAL SPECIMENS CURRENTLY UNDERGOING IMMUNOPROFILING WITH OTHER DIAGNOSTIC METHODS. CLINICAL SAMPLE STUDIES WILL BE OVERSEEN BY AN ADVISORY GROUP OF BOARD-CERTIFIED HMS PATHOLOGISTS.
$847.8k
8/9/21
Not listed
RAPID HIGHLY MULTI-PLEXED IMMUNO-PROFILING OF SOLID TUMORS BY SPECTRALEDGE IMAGING - PROJECT SUMMARY - ABSTRACT THE DRAMATIC IMPACT OF IMMUNE CHECKPOINT INHIBITORS (ICIS) HAS FOCUSED INTEREST IN INVESTIGATING IMMUNE-TUMOR CELL INTERACTIONS TO UNDERSTAND MECHANISMS OF ICI SENSITIVITY AND RESISTANCE, TO IDENTIFY PATIENTS RESPONSIVE TO SPECIFIC DRUGS, AND TO DEVELOP NEW THERAPIES. MULTIPLEXED TISSUE IMAGING IS A HIGHLY PROMISING APPROACH TO TUMOR IMMUNOPROFILING: IT CAN ASSESS MANY CELL TYPES AND STATES WITHIN THE CONTEXT OF PRESERVED TUMOR ARCHITECTURE AND IS COMPATIBLE WITH PATHOLOGY WORKFLOWS. A CRITICAL UNMET NEED EXISTS FOR MULTIPLEX TECHNOLOGY WITH THE FOLLOWING CAPABILITIES: (1) WHOLE-SLIDE IMAGING; (2) RAPID SINGLE-PASS DATA COLLECTION; (3) SUB- CELLULAR IMAGING RESOLUTION; (4) SUFFICIENT IMMUNOPROFILING DEPTH; (5) BRIGHT-FIELD IMAGING CAPABILITY; (6) OPTICAL AND MECHANICAL STABILITY FOR ACCURATE IMAGE TILE STITCHING; (7) AVAILABILITY OF CORE AND CUSTOMIZABLE ANTIBODY PANEL KITS FOR PROFILING; AND (8) COMPATIBILITY WITH ESTABLISHED IMAGE DATA STANDARDS AND FORMATS. THIS RARECYTE - HARVARD MEDICAL SCHOOL PHASE II PROPOSAL DESCRIBES SPECTRALEDGETM, A BREAKTHROUGH IMAGING TECHNOLOGY THAT MEETS THESE REQUIREMENTS, PERFORMING HIGH-RESOLUTION HIGH-PLEX WHOLE-SLIDE IMAGING OF 20 ANTIGENS LABELLED WITH FLUOROPHORE-CONJUGATED ANTIBODIES IN A SINGLE-PASS SCAN OF LESS THAN 1 HOUR. THE PATENTED SPECTRALEDGE METHOD INVOLVES A NOVEL INSTRUMENT AND SOFTWARE AS WELL AS HIGHLY VALIDATED TISSUEPLEXTM ANTIBODY PANELS. SPECTRALEDGE IMAGING WILL ACCELERATE DISCOVERY OF PREDICTIVE AND PROGNOSTIC BIOMARKERS, ENABLE PHARMACODYNAMICS STUDY OF IMMUNO-ONCOLOGY DRUGS UNDERGOING CLINICAL TRIALS AND ULTIMATELY PROVIDE CLINICALLY ACTIONABLE DIAGNOSTIC TESTS. AIM 1 WILL FOCUS ON ENGINEERING AND PRODUCTION OF A ROBUST, PRODUCTION-READY SLIDE SCANNER AND SOFTWARE FOR RAPID HIGH-RESOLUTION 20-PLEX SPECTRALEDGE WHOLE-SLIDE IMAGING; IT WILL BE BASED ON RARECYTE'S EXISTING CYTEFINDER II IMAGING SYSTEM. PRODUCTION OF A RESEARCH-USE-ONLY INSTRUMENT AND REAGENTS TO ISO13485 STANDARDS WILL ENABLE SUBSEQUENT DEPLOYMENT IN A CLINICAL SETTING. COMPATIBILITY WITH CURRENT AND EMERGING DATA FORMAT AND SOFTWARE STANDARDS WILL ENABLE INTEGRATION WITH DIVERSE RESEARCH AND CLINICAL WORKSTREAMS. AIM 2 WILL TEST AND VALIDATE MODULAR ANTIBODY PANELS FOR IMMUNOPHENOTYPING AND TUMOR CELL IMAGING ACROSS A RANGE OF TUMOR TYPES. THIS WILL YIELD VALIDATED TISSUEPLEX PANELS HAVING A CORE SET OF IMMUNOPROFILING ANTIBODIES AND ANTIBODY "MODULES" FOR INDIVIDUAL TUMOR TYPES. AIM 3 WILL TEST SPECTRALEDGE IMAGING ON WELL-CHARACTERIZED SAMPLE COHORTS IN: (I) TRANSLATIONAL BIOMARKER DISCOVERY, (II) INDUSTRY-SPONSORED AND INVESTIGATOR-INITIATED IMMUNO-ONCOLOGY TRIALS, (III) MOUSE MODELS OF CANCER, AND (IV) CLINICAL SPECIMENS CURRENTLY UNDERGOING IMMUNOPROFILING WITH OTHER DIAGNOSTIC METHODS. CLINICAL SAMPLE STUDIES WILL BE OVERSEEN BY AN ADVISORY GROUP OF BOARD-CERTIFIED HMS PATHOLOGISTS.
$847.8k
8/9/21
Not listed
RAPID HIGHLY MULTI-PLEXED IMMUNO-PROFILING OF SOLID TUMORS BY SPECTRALEDGE IMAGING - PROJECT SUMMARY - ABSTRACT THE DRAMATIC IMPACT OF IMMUNE CHECKPOINT INHIBITORS (ICIS) HAS FOCUSED INTEREST IN INVESTIGATING IMMUNE-TUMOR CELL INTERACTIONS TO UNDERSTAND MECHANISMS OF ICI SENSITIVITY AND RESISTANCE, TO IDENTIFY PATIENTS RESPONSIVE TO SPECIFIC DRUGS, AND TO DEVELOP NEW THERAPIES. MULTIPLEXED TISSUE IMAGING IS A HIGHLY PROMISING APPROACH TO TUMOR IMMUNOPROFILING: IT CAN ASSESS MANY CELL TYPES AND STATES WITHIN THE CONTEXT OF PRESERVED TUMOR ARCHITECTURE AND IS COMPATIBLE WITH PATHOLOGY WORKFLOWS. A CRITICAL UNMET NEED EXISTS FOR MULTIPLEX TECHNOLOGY WITH THE FOLLOWING CAPABILITIES: (1) WHOLE-SLIDE IMAGING; (2) RAPID SINGLE-PASS DATA COLLECTION; (3) SUB- CELLULAR IMAGING RESOLUTION; (4) SUFFICIENT IMMUNOPROFILING DEPTH; (5) BRIGHT-FIELD IMAGING CAPABILITY; (6) OPTICAL AND MECHANICAL STABILITY FOR ACCURATE IMAGE TILE STITCHING; (7) AVAILABILITY OF CORE AND CUSTOMIZABLE ANTIBODY PANEL KITS FOR PROFILING; AND (8) COMPATIBILITY WITH ESTABLISHED IMAGE DATA STANDARDS AND FORMATS. THIS RARECYTE - HARVARD MEDICAL SCHOOL PHASE II PROPOSAL DESCRIBES SPECTRALEDGETM, A BREAKTHROUGH IMAGING TECHNOLOGY THAT MEETS THESE REQUIREMENTS, PERFORMING HIGH-RESOLUTION HIGH-PLEX WHOLE-SLIDE IMAGING OF 20 ANTIGENS LABELLED WITH FLUOROPHORE-CONJUGATED ANTIBODIES IN A SINGLE-PASS SCAN OF LESS THAN 1 HOUR. THE PATENTED SPECTRALEDGE METHOD INVOLVES A NOVEL INSTRUMENT AND SOFTWARE AS WELL AS HIGHLY VALIDATED TISSUEPLEXTM ANTIBODY PANELS. SPECTRALEDGE IMAGING WILL ACCELERATE DISCOVERY OF PREDICTIVE AND PROGNOSTIC BIOMARKERS, ENABLE PHARMACODYNAMICS STUDY OF IMMUNO-ONCOLOGY DRUGS UNDERGOING CLINICAL TRIALS AND ULTIMATELY PROVIDE CLINICALLY ACTIONABLE DIAGNOSTIC TESTS. AIM 1 WILL FOCUS ON ENGINEERING AND PRODUCTION OF A ROBUST, PRODUCTION-READY SLIDE SCANNER AND SOFTWARE FOR RAPID HIGH-RESOLUTION 20-PLEX SPECTRALEDGE WHOLE-SLIDE IMAGING; IT WILL BE BASED ON RARECYTE'S EXISTING CYTEFINDER II IMAGING SYSTEM. PRODUCTION OF A RESEARCH-USE-ONLY INSTRUMENT AND REAGENTS TO ISO13485 STANDARDS WILL ENABLE SUBSEQUENT DEPLOYMENT IN A CLINICAL SETTING. COMPATIBILITY WITH CURRENT AND EMERGING DATA FORMAT AND SOFTWARE STANDARDS WILL ENABLE INTEGRATION WITH DIVERSE RESEARCH AND CLINICAL WORKSTREAMS. AIM 2 WILL TEST AND VALIDATE MODULAR ANTIBODY PANELS FOR IMMUNOPHENOTYPING AND TUMOR CELL IMAGING ACROSS A RANGE OF TUMOR TYPES. THIS WILL YIELD VALIDATED TISSUEPLEX PANELS HAVING A CORE SET OF IMMUNOPROFILING ANTIBODIES AND ANTIBODY "MODULES" FOR INDIVIDUAL TUMOR TYPES. AIM 3 WILL TEST SPECTRALEDGE IMAGING ON WELL-CHARACTERIZED SAMPLE COHORTS IN: (I) TRANSLATIONAL BIOMARKER DISCOVERY, (II) INDUSTRY-SPONSORED AND INVESTIGATOR-INITIATED IMMUNO-ONCOLOGY TRIALS, (III) MOUSE MODELS OF CANCER, AND (IV) CLINICAL SPECIMENS CURRENTLY UNDERGOING IMMUNOPROFILING WITH OTHER DIAGNOSTIC METHODS. CLINICAL SAMPLE STUDIES WILL BE OVERSEEN BY AN ADVISORY GROUP OF BOARD-CERTIFIED HMS PATHOLOGISTS.
$0
10/14/20
Not listed
RAPID HIGHLY MULTI-PLEXED IMMUNO-PROFILING OF SOLID TUMORS BY SPECTRALEDGE IMAGING - PROJECT SUMMARY - ABSTRACT THE DRAMATIC IMPACT OF IMMUNE CHECKPOINT INHIBITORS (ICIS) HAS FOCUSED INTEREST IN INVESTIGATING IMMUNE-TUMOR CELL INTERACTIONS TO UNDERSTAND MECHANISMS OF ICI SENSITIVITY AND RESISTANCE, TO IDENTIFY PATIENTS RESPONSIVE TO SPECIFIC DRUGS, AND TO DEVELOP NEW THERAPIES. MULTIPLEXED TISSUE IMAGING IS A HIGHLY PROMISING APPROACH TO TUMOR IMMUNOPROFILING: IT CAN ASSESS MANY CELL TYPES AND STATES WITHIN THE CONTEXT OF PRESERVED TUMOR ARCHITECTURE AND IS COMPATIBLE WITH PATHOLOGY WORKFLOWS. A CRITICAL UNMET NEED EXISTS FOR MULTIPLEX TECHNOLOGY WITH THE FOLLOWING CAPABILITIES: (1) WHOLE-SLIDE IMAGING; (2) RAPID SINGLE-PASS DATA COLLECTION; (3) SUB- CELLULAR IMAGING RESOLUTION; (4) SUFFICIENT IMMUNOPROFILING DEPTH; (5) BRIGHT-FIELD IMAGING CAPABILITY; (6) OPTICAL AND MECHANICAL STABILITY FOR ACCURATE IMAGE TILE STITCHING; (7) AVAILABILITY OF CORE AND CUSTOMIZABLE ANTIBODY PANEL KITS FOR PROFILING; AND (8) COMPATIBILITY WITH ESTABLISHED IMAGE DATA STANDARDS AND FORMATS. THIS RARECYTE - HARVARD MEDICAL SCHOOL PHASE II PROPOSAL DESCRIBES SPECTRALEDGETM, A BREAKTHROUGH IMAGING TECHNOLOGY THAT MEETS THESE REQUIREMENTS, PERFORMING HIGH-RESOLUTION HIGH-PLEX WHOLE-SLIDE IMAGING OF 20 ANTIGENS LABELLED WITH FLUOROPHORE-CONJUGATED ANTIBODIES IN A SINGLE-PASS SCAN OF LESS THAN 1 HOUR. THE PATENTED SPECTRALEDGE METHOD INVOLVES A NOVEL INSTRUMENT AND SOFTWARE AS WELL AS HIGHLY VALIDATED TISSUEPLEXTM ANTIBODY PANELS. SPECTRALEDGE IMAGING WILL ACCELERATE DISCOVERY OF PREDICTIVE AND PROGNOSTIC BIOMARKERS, ENABLE PHARMACODYNAMICS STUDY OF IMMUNO-ONCOLOGY DRUGS UNDERGOING CLINICAL TRIALS AND ULTIMATELY PROVIDE CLINICALLY ACTIONABLE DIAGNOSTIC TESTS. AIM 1 WILL FOCUS ON ENGINEERING AND PRODUCTION OF A ROBUST, PRODUCTION-READY SLIDE SCANNER AND SOFTWARE FOR RAPID HIGH-RESOLUTION 20-PLEX SPECTRALEDGE WHOLE-SLIDE IMAGING; IT WILL BE BASED ON RARECYTE'S EXISTING CYTEFINDER II IMAGING SYSTEM. PRODUCTION OF A RESEARCH-USE-ONLY INSTRUMENT AND REAGENTS TO ISO13485 STANDARDS WILL ENABLE SUBSEQUENT DEPLOYMENT IN A CLINICAL SETTING. COMPATIBILITY WITH CURRENT AND EMERGING DATA FORMAT AND SOFTWARE STANDARDS WILL ENABLE INTEGRATION WITH DIVERSE RESEARCH AND CLINICAL WORKSTREAMS. AIM 2 WILL TEST AND VALIDATE MODULAR ANTIBODY PANELS FOR IMMUNOPHENOTYPING AND TUMOR CELL IMAGING ACROSS A RANGE OF TUMOR TYPES. THIS WILL YIELD VALIDATED TISSUEPLEX PANELS HAVING A CORE SET OF IMMUNOPROFILING ANTIBODIES AND ANTIBODY "MODULES" FOR INDIVIDUAL TUMOR TYPES. AIM 3 WILL TEST SPECTRALEDGE IMAGING ON WELL-CHARACTERIZED SAMPLE COHORTS IN: (I) TRANSLATIONAL BIOMARKER DISCOVERY, (II) INDUSTRY-SPONSORED AND INVESTIGATOR-INITIATED IMMUNO-ONCOLOGY TRIALS, (III) MOUSE MODELS OF CANCER, AND (IV) CLINICAL SPECIMENS CURRENTLY UNDERGOING IMMUNOPROFILING WITH OTHER DIAGNOSTIC METHODS. CLINICAL SAMPLE STUDIES WILL BE OVERSEEN BY AN ADVISORY GROUP OF BOARD-CERTIFIED HMS PATHOLOGISTS.
$0
10/14/20